From March 2013 to July 2016 individuals received intravitreal aflibercept 2?mg in 0

From March 2013 to July 2016 individuals received intravitreal aflibercept 2?mg in 0.05?mL. were 42 eyes in bevacizumab group, with mean age of 53.2??5.4 years and 27 female individuals of them. The mean BCVA significantly improved from baseline 0.56??0.35 logMAR to 0.35??0.35 logMAR at Month 12 after bevacizumab treatment (p? ?0.001). The mean CFT significantly decreased from baseline 315.3??25.6 m to 253.7??24.4 m at Month 12 following intravitreal bevacizumab (p? ?0.001). There were 36 eyes in aflibercept group, with mean age of 52.8??6.8 years and 24 female individuals of them. The mean BCVA significantly improved from baseline 0.61??0.47 logMAR to 0.38??0.41 logMAR at Month 12 after aflibercept treatment (p? ?0.001). The mean CFT significantly decreased from baseline 328.2??19.8 m to 241.8??27.2 m at Month 12 following intravitreal aflibercept (p? ?0.001). The baseline demographics, lens status, axial Fevipiprant size, refractive errors, duration of symptoms, BCVA, and CFT did not differ significantly between organizations (p? ?0.05). There was no significant difference between bevacizumab and aflibercept organizations in BCVA and CFT from Month 1 to Month 12 (p? ?0.05). Injection quantity of aflibercept was 2.11??0.41, less than that of bevacizumab (3.23??0.38) during 12-month period (p?=?0.01). There were no systemic thromboembolic event, elevated intraocular pressure, retinal detachment, or infectious endophthalmitis following injections in both organizations. We concluded that both aflibercept and bevacizumab can efficiently treat choroidal neovascularization in high myopes. Intravitreal aflibercept experienced similar effectiveness but less treatment quantity than bevacizumab for mCNV during 12-month period. Intro Subfoveal or juxtafoveal myopic choroidal neovascularization (mCNV) is an important cause of visual impairment in highly myopic individuals1,2. Elevated intraocular level of vascular endothelial growth element (VEGF) was associated with formation of mCNV3. Intravitreal administration of different anti-VEGF providers was proven to be effective for treating mCNV, such as bevacizumab (Avastin?, Genentech Inc., South San Francisco, CA, USA), and aflibercept (Eylea?, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, and Bayer Pharma AG, Berlin, Germany)4C19. Bevacizumab and aflibercept showed greater ability to manage mCNV than Fevipiprant either verteporfin photodynamic therapy or sham injections in prior randomized control tests4,5,16. However, head-to-head assessment of effectiveness between bevacizumab and aflibercept for mCNV was lacking. To our knowledge, this was the 1st study to compare the medical results of bevacizumab and aflibercept in treating mCNV. Methods The protocol of the study which adopted the Declaration of Helsinki was authorized by institutional review table of Far Eastern Memorial Hospital in Taiwan. All the individuals authorized the educated consent to agree receiving intravitreal injections and participating the study. This is a retrospective, comparative, and non-randomized study. Individuals with treatment-na?ve mCNV were consecutively collected. All the highly myopic individuals had age more than 18 years and axial size more than 26?mm. Pseudophakic and phakic individuals were allowed for inclusion. They presented with best-corrected visual acuity (BCVA) between 20/400 to 20/40, subfoveal or juxtafoveal choroidal neovascularization with or without intramacular or submacular fluid on spectral website optical coherence tomography (SD-OCT, RTVue, Optovue Inc., San Francisco, CA, USA) using 6 radial collection scans through the fovea, submacular leakage on fundus fluorescein angiography (TRC-NW7SF, Topcon Inc., Tokyo, Japan), with or without accompanying submacular hemorrhage on fundus color pictures. We excluded pregnant or nursing ladies, and also the individuals with the history of thromboembolic events, major surgery treatment within the previous 3 months or planned within the next 28 days, uncontrolled hypertension, known coagulation abnormalities or current use of anticoagulative medication other than aspirin, prior macular photocoagulation or photodynamic therapy, prior intraocular surgeries within 3 months, presence of active infectious disease or intraocular swelling, intraocular pressure more than 25?mmHg, or presence of iris neovascularization/vitreous hemorrhage. Almost all the individuals with treatment-na?ve mCNV received bevacizumab treatment in our clinics before March 2013. Aflibercept was available after March 2013, and we mostly changed the first-line therapy to aflibercept for mCNV. Individuals treated Fevipiprant from March 2008 to February 2013 received intravitreal bevacizumab Rabbit Polyclonal to MRPS31 1.25?mg in 0.05?mL. From March 2013 to July 2016 individuals received intravitreal aflibercept 2?mg in 0.05?mL. Aflibercept or bevacizumab was performed 1?+?PRN injection intravitreally with month to month follow-up for at least 12 months. The 1?+?PRN routine included baseline treatment and then retreatment while one or more of the criteria were met as follows: Fevipiprant (1) BCVA decrease equal or more than one line from the previous visual exam; (2) central foveal thickness (CFT) increase equivalent or more than 50 m from the previous SD-OCT exam; (3) Prolonged or recurrent cystic macular changes, submacular fluid, or pigment epithelial detachment on SD-OCT; (4) Persistent or recurrent submacular hemorrhage within the fundus exam. BCVA in Snellen chart (transforming into logMAR and EDTRS characters for statistical assessment)20, intraocular pressure via pneumotonometer (CT-80, Topcon Inc., Tokyo, Japan), biomicroscope of anterior section, SD-OCT of macula, and fundus color pictures were.